SciBase presents at the Skin cancer: What's new in 2026 congress in Bologna

SWEDEN – November 27, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, announced that Jvalini Dwarkasing Chief Medical Officer at SciBase, today presented Nevisense and electrical impedance spectroscopy (EIS) at the Skin Cancer: What's new in 2026 congress in Bologna, Italy.

Skin Cancer – What's New 2026 is an 8-hour, in-person continuing medical education (CME/ECM) event organized by the University of Bologna on melanoma and non-melanoma skin cancers taking place on November 27, 2026, at Aula Poeti, Palazzo Hercolani (Strada Maggiore 45) in Bologna, Italy.



"*Italy is a key market in Europe and educating dermatologists and KOL's regarding Nevisense and our technology is a step towards establishing us as an integral part of skin cancer assessment. Reimbursement is key to penetrating the Italian market and this kind of event supports that process as well.*," said Pia Renaudin CEO of SciBase.

SciBase is together with its partner Kilabs S.r.l working to integrate Nevisense into clinical practice, offering a more accurate and non-invasive method for early melanoma detection, which could significantly improve patient outcomes in the field of dermatology.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

About Kilabs

Kilabs is an organization dedicated to advancing research, development and access to cutting-edge solutions in specialized medical fields. https://www.kilabspharma.it/en/